Prime Medicine Inc (NASDAQ: PRME) kicked off on Monday, up 10.46% from the previous trading day, before settling in for the closing price of $4.35. Over the past 52 weeks, PRME has traded in a range of $1.11-$6.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -124.13% over the past five years. While this was happening, its average annual earnings per share was recorded 23.53%. With a float of $51.64 million, this company’s outstanding shares have now reached $131.16 million.
Let’s look at the performance matrix of the company that is accounted for 214 employees. In terms of profitability, gross margin is 95.87%, operating margin of -496.2%, and the pretax margin is -485.69%.
Prime Medicine Inc (PRME) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 60.67%, while institutional ownership is 28.99%. The most recent insider transaction that took place on Jun 30 ’25, was worth 52,830. In this transaction 10% Owner of this company bought 21,000 shares at a rate of $2.52, taking the stock ownership to the 20,240,945 shares. Before that another transaction happened on Jun 23 ’25, when Company’s 10% Owner bought 21,000 for $2.16, making the entire transaction worth $45,402. This insider now owns 20,219,945 shares in total.
Prime Medicine Inc (PRME) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.43% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Take a look at Prime Medicine Inc’s (PRME) current performance indicators. Last quarter, stock had a quick ratio of 4.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 163.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 6.23 million, a positive change from its year-to-date volume of 2.13 million. As of the previous 9 days, the stock’s Stochastic %D was 91.50%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 99.19%, which indicates a significant increase from 98.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.49 in the past 14 days, which was higher than the 0.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.99, while its 200-day Moving Average is $2.63. Nevertheless, the first resistance level for the watch stands at $5.01 in the near term. At $5.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.61. If the price goes on to break the first support level at $4.42, it is likely to go to the next support level at $4.03. Assuming the price breaks the second support level, the third support level stands at $3.82.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
The company with the Market Capitalisation of 630.87 million has total of 134,494K Shares Outstanding. Its annual sales at the moment are 2,980 K in contrast with the sum of -195,880 K annual income. Company’s last quarter sales were recorded 1,450 K and last quarter income was -51,890 K.
